🇺🇸 FDA
Patent

US 11396647

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

granted A61KA61K2039/505A61K38/45

Quick answer

US patent 11396647 (Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K38/45, A61K39/395, A61K45/06